NYSE$LCTX
Lineage Cell Therapeutics In · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2023.
Lineage Cell Therapeutics reported a net loss of $7.1 million, or $0.04 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, expected to support operations into Q1 2025. Total revenues for the quarter were $1.2 million.
- Lineage team continued to advance clinical and preclinical pipeline.
- Continued to support Phase 2a clinical study of OpRegen in patients with geographic atrophy secondary to AMD with Roche and Genentech.
- Working on IND amendment submission for OPC1 to initiate DOSED clinical study in spinal cord injury patients.
- Initiated development activities under partnership with Eterna Therapeutics.
Headline financials
Revenue & EPS history
Lineage · Revenue · Quarterly
$1.25M
Revenue by segment
Lineage · $700K total across 1 segment · Q4 2019
- Royalties and licensing$700K—100.0%
Forward guidance
Cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, which is expected to support planned operations into Q1 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
50%
31 / 62 earnings
Positive
+16.6%
Q4 2016
Best reaction
-14.5%
Q1 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.5% | -4.6% | — | |
| Q4 2025 | +0.5% | -8.7% | -14.7% | |
| Q3 2025 | +1.2% | +11.6% | -0.6% | |
| Q1 2025 | -0.1% | +6.4% | +72.3% | |
| Q4 2024 | +0.4% | -1.9% | -22.6% | |
| Q3 2024 | -5.3% | -1.1% | -44.0% | |
| Q2 2024 | +4.4% | -4.6% | -3.4% | |
| Q1 2024 | +0.9% | -10.3% | -16.4% | |
| Q4 2023 | +15.0% | +9.7% | +23.9% | |
| Q3 2023 | -5.5% | -8.2% | -5.5% | |
| Q2 2023 | +0.0% | +1.4% | -5.6% | |
| Q1 2023 | -3.5% | -4.9% | -3.5% | |
| Q4 2022 | -2.1% | -4.8% | -6.2% | |
| Q3 2022 | +15.2% | +4.8% | -2.4% | |
| Q2 2022 | +0.6% | -3.2% | -16.7% | |
| Q1 2022 | -5.9% | +1.7% | +17.6% | |
| Q4 2021 | -5.6% | -14.8% | -3.5% | |
| Q3 2021 | -0.4% | +0.4% | -19.0% | |
| Q2 2021 | -1.1% | -7.9% | -12.1% | |
| Q1 2021 | -0.4% | +0.9% | +26.4% | |
| Q4 2020 | +10.2% | +21.0% | +32.3% | |
| Q3 2020 | +7.4% | +7.4% | +32.0% | |
| Q2 2020 | +3.7% | +2.3% | -2.3% | |
| Q1 2020 | -3.7% | -11.5% | -7.3% | |
| Q4 2019 | -5.3% | -12.7% | -2.5% | |
| Q3 2019 | +6.6% | +19.2% | -5.5% | |
| Q2 2019 | -8.9% | -8.9% | -8.9% | |
| Q1 2019 | +0.8% | -10.8% | -16.7% | |
| Q4 2018 | +10.2% | +0.0% | -17.8% | |
| Q3 2018 | -8.6% | -17.1% | -27.1% | |
| Q2 2018 | -3.7% | -4.6% | +14.1% | |
| Q1 2018 | +0.9% | +2.3% | +3.7% | |
| Q4 2017 | +0.7% | -4.3% | -10.1% | |
| Q3 2017 | +14.3% | +6.3% | +8.5% | |
| Q2 2017 | +6.4% | +6.0% | +8.3% | |
| Q1 2017 | +0.3% | +1.9% | +1.6% | |
| Q4 2016 | +16.6% | +5.5% | +5.8% | |
| Q3 2016 | +0.3% | +0.3% | +1.3% | |
| Q2 2016 | -5.4% | -6.0% | +5.1% | |
| Q1 2016 | -4.6% | — | — | |
| Q4 2015 | +9.5% | — | — | |
| Q3 2015 | -7.6% | — | — | |
| Q2 2015 | -6.2% | — | — | |
| Q4 2014 | +1.2% | — | — | |
| Q3 2014 | +0.3% | — | — | |
| Q1 2014 | +6.4% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q3 2013 | -1.8% | — | — | |
| Q2 2013 | +0.5% | — | — | |
| Q1 2013 | +8.5% | — | — | |
| Q4 2012 | -9.5% | — | — | |
| Q3 2012 | -4.5% | — | — | |
| Q2 2012 | -4.3% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -7.1% | — | — | |
| Q2 2011 | +3.0% | — | — | |
| Q1 2011 | -2.9% | — | — | |
| Q4 2010 | -4.7% | — | — | |
| Q3 2010 | +6.9% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q1 2010 | -14.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro